Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P990065/S019

SIR-Spheres Y-90 resin microspheres

Sirtex Medical, Inc. · Decision date May 7, 2026

FDA DECISIONP990065/S019

What did the FDA decide?

FDA records P990065/S019 as a supplement to PMA P990065, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 7, 2026.

FDA approval order statement

a process change to allow for an additional volume size (SIR-Y003, 0.6 GBq/1 mL) to the existing SIR-Spheres Y-90 resin microspheres product line
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Radiology
Decision date
May 7, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P990065/S019
Regulatory pathway
PMA supplement
Product code
NAW
Decision code
OK30
Decision date
May 7, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Microspheres radionuclide.

Product code
NAW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P990065/S019 received

    Application receipt date recorded by FDA.

  2. P990065/S019 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P990065. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

Other records with product code NAW

Product / regulatory recordCompanyPathwayDecision dateSource
BOSTON SCIENTIFIC CORPORATIONPMA supplementOct 13, 2026FDA
TheraSphereP200029/S014
BOSTON SCIENTIFIC CORPORATIONPMA supplementAug 21, 2026FDA
BOSTON SCIENTIFIC CORPORATIONPMA supplementJun 4, 2026FDA
TheraSphereP200029/S012
BOSTON SCIENTIFIC CORPORATIONPMA supplementApr 10, 2026FDA
TheraSphereP200029/S011
BOSTON SCIENTIFIC CORPORATIONPMA supplementFeb 10, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Sirtex Medical, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
300 Unicorn Park Dr., 2nd Floor ,, Woburn, MA, 01801

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records